Somatostatinoma Completed Phase 2 Trials for Sorafenib (DB00398)

Also known as: Somatostatinomas

IndicationStatusPhase
DBCOND0000820 (Somatostatinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00131911Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine TumorsTreatment